The purpose of this guidance is to provide clarity on the approval process for the prescribing of the second-generation antipsychotic long-acting injections within Lancashire Care NHS Foundation Trust.
This position statement relates to the use of tapentadol MR for the following indications:
1. As a treatment option for intractable neuropathic pain in non-palliative care patients
2. As a treatment for nonspecific pain
Tapentadol Non Palliative Neuropathic Pain New Medicine Assessment